Health Care

Rhythm Biosciences (RHY) has added the primary care division of medical giant Sonic Healthcare (SHL) to its ColoSTAT clinical trial.

Regenerative medicine company Orthocell (OCC) has secured Chinese and New Zealand patents for its novel CelGro collagen medical device for soft tissue regeneration.

A new study featuring Patrys’ (PAD) PAT-DX1 candidate has demonstrated its ability to inhibit the growth of primary and secondary brain cancers.

With the prevailing strength of its RECELL System, Avita Medical (AVH) has elected to increase its fourth-quarter revenue guidance.

Nyrada’s (NYR) new lead drug candidate has advanced to efficacy studies with the Walter Reed Army Institute of Research (WRAIR).

Zelira Therapeutics (ZLD) has signed a five-year distribution with Health House International (HHI) to launch CBD toothpaste in the UK.

Kazia Therapeutics (KZA) will collaborate with Cornell University to investigate Kazia’s new brain cancer treatment in combination with a keto diet.

Invex Therapeutics (IXC) is reviewing its upcoming Presendin hypertension treatment trial after receiving feedback from the US Food and Drug Administration.

Argenica Therapeutics (AGN) has finished its first day of trade on the ASX, following a well supported initial public offering.